- Ability to consent to the procedure

- Age 18 - 80

- Intra-abdominal fluid collection thought to be an

abscess which when a drain was inserted, returned

purulent fluid and that has not been previously

percutaneously drained but requires

percutaneous drainage.

- Inappropriate antibiotic coverage prior to the drainage procedure

- Pregnancy or lactating

- Child bearing potential who is not using a reliable method of contraception

- Previous allergic reaction to TPA

- Pancreatic pseudocysts and collections thought to be hematomas

- Inability or unwillingness to consent to the procedure

- Treatment with any investigational drug or investigational biologic within 30

days of initiating study treatment

- Scheduled major surgery during the study period

- Concomitant administration of unfractionated heparin intravenously for the

purpose of systemic anticoagulation

- Patients with a baseline platelet count < 50,000/ul, INR > 1.6 (when not

corrected with fresh frozen plasma at the time of the procedure)

- Known coagulopathy, systemic therapeutic anticoagulation or any condition in

which bleeding constitutes a significant hazard or would be particularly difficult

to manage because of its location, or who are at high risk for embolic

complications (e.g., recent pulmonary embolism, deep vein thrombosis,

endarterectomy)

- Major hemorrhage within the previous 4 weeks, defined as bleeding resulting in

a drop in hemoglobin of greater than 20 g/L or bleeding requiring transfusion of

packed red blood cells with other clinical evidence or suspicion of bleeding

- History of intracranial hemorrhage within the 4 weeks prior to drainagee prior to

the drainage procedure

- Child bearing potential who is not using a reliable method of contraception

- Previous allergic reaction to TPA

- Pancreatic pseudocysts and collections thought to be hematomas

- Inability or unwillingness to consent to the procedure

- Treatment with any investigational drug or investigational biologic within 30

days of initiating study treatment

- Scheduled major surgery during the study period

- Concomitant administration of unfractionated heparin intravenously for the

purpose of systemic anticoagulation

- Patients with a baseline platelet count < 50,000/ul, INR > 1.6 (when not

corrected with fresh frozen plasma at the time of the procedure)

- Known coagulopathy, systemic therapeutic anticoagulation or any condition in

which bleeding constitutes a significant hazard or would be particularly difficult

to manage because of its location, or who are at high risk for embolic

complications (e.g., recent pulmonary embolism, deep vein thrombosis,

endarterectomy)

- Major hemorrhage within the previous 4 weeks, defined as bleeding resulting in

a drop in hemoglobin of greater than 20 g/L or bleeding requiring transfusion of

packed red blood cells with other clinical evidence or suspicion of bleeding

- History of intracranial hemorrhage within the 4 weeks prior to drainage